<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: To evaluate the use of biological response modifiers (BRM) in the treatment of refractory childhood <z:hpo ids='HP_0000554'>uveitis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>DESIGN: Retrospective non-comparative case series of pediatric patients with <z:hpo ids='HP_0000554'>uveitis</z:hpo> treated with BRM </plain></SENT>
<SENT sid="2" pm="."><plain>PARTICIPANTS: 23 pediatric patients </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: <z:hpo ids='HP_0000001'>All</z:hpo> children (18 years or younger) who received a BRM were assessed for visual changes, time to control <z:mp ids='MP_0001845'>inflammation</z:mp>, and any associated adverse side effects </plain></SENT>
<SENT sid="4" pm="."><plain>Thirteen patients were treated with infliximab, five with adalimumab, and five with daclizumab </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients had bilateral eye involvement </plain></SENT>
<SENT sid="6" pm="."><plain>Diagnoses of the participants included juvenile idiopathic <z:hpo ids='HP_0001369'>arthritis</z:hpo>, <z:e sem="disease" ids="C1299910" disease_type="Disease or Syndrome" abbrv="">keratouveitis</z:e>, <z:e sem="disease" ids="C0036202" disease_type="Disease or Syndrome" abbrv="">sarcoid</z:e> <z:hpo ids='HP_0012121'>panuveitis</z:hpo>, <z:e sem="disease" ids="C0004943" disease_type="Disease or Syndrome" abbrv="">Adamantiades-Behcets disease</z:e>, and idiopathic <z:hpo ids='HP_0012121'>panuveitis</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>MAIN OUTCOME MEASURES: <z:mp ids='MP_0001845'>Inflammation</z:mp> and visual acuity </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: In the infliximab group 16 of 26 eyes (62%), and 10 of 13 patients (77%) demonstrated an improvement in visual acuity </plain></SENT>
<SENT sid="9" pm="."><plain>Twenty of 26 eyes (77%) demonstrated an improvement in the degree of <z:mp ids='MP_0001845'>inflammation</z:mp> </plain></SENT>
<SENT sid="10" pm="."><plain>In the adalimumab group, four of 10 eyes (40%) demonstrated an improvement in visual acuity, with five of 10 eyes (50%) demonstrating an improvement in <z:mp ids='MP_0001845'>inflammation</z:mp> </plain></SENT>
<SENT sid="11" pm="."><plain>Four of 10 eyes (40%) in the daclizumab group demonstrated an improvement in vision with eight of 10 eyes (80%) demonstrating an improvement in <z:mp ids='MP_0001845'>inflammation</z:mp> </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSION: BRM appear to be safe to use in children, and represent a useful therapeutic adjunctive drug group for treating recalcitrant childhood <z:hpo ids='HP_0000554'>uveitis</z:hpo> </plain></SENT>
</text></document>